Skip to content

BIOREGENX, INC.: 10-Q filed 2024-11-14

What BIOREGENX, INC. reported in its quarterly report filed 2024-11-14 (fiscal Q3 2024): 46 published measures, 130 facts as tagged in accession 0001683168-24-008044.

This filing

Form
10-Q (quarterly report)
Filed
2024-11-14
Fiscal period
fiscal Q3 2024
Accession
0001683168-24-008044 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOREGENX, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-09-3017,361,364USD
At 2023-12-31865,750USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-09-303,800,594USD
At 2023-12-312,937,177USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-09-3013,560,770USD
At 2024-06-3014,221,236USD
At 2023-12-31-2,071,427USD
At 2023-09-30-2,798,005USD
At 2023-06-30-2,580,662USD
At 2022-12-31-2,527,938USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-09-3070,081USD
At 2023-12-31125,402USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-394,860USD92
2024-01-01 to 2024-09-30-4,653,446USD274
2023-07-01 to 2023-09-30-2,519,035USD92
2023-01-01 to 2023-09-30-3,343,334USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-312,787USD274
2023-01-01 to 2023-09-30-1,269,417USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2024-01-01 to 2024-09-30189,390USD274
2023-01-01 to 2023-09-300USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2024-07-01 to 2024-09-30596,037USD92
2024-01-01 to 2024-09-301,879,617USD274
2023-07-01 to 2023-09-30794,544USD92
2023-01-01 to 2023-09-302,733,407USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-09-30449,063USD274
2023-01-01 to 2023-09-30690,952USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-190,597USD274
2023-01-01 to 2023-09-300USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-09-30-17,171,424USD
At 2023-12-31-12,517,978USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-07-01 to 2024-09-30956,530,100shares92
2024-01-01 to 2024-09-30928,777,082shares274
2023-07-01 to 2023-09-30621,921,192shares92
2023-01-01 to 2023-09-30620,755,525shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-07-01 to 2024-09-30956,530,100shares92
2024-01-01 to 2024-09-30928,777,082shares274
2023-07-01 to 2023-09-30621,921,192shares92
2023-01-01 to 2023-09-30620,755,525shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-07-01 to 2024-09-300USD/shares92
2024-01-01 to 2024-09-30-0.01USD/shares274
2023-07-01 to 2023-09-300USD/shares92
2023-01-01 to 2023-09-30-0.01USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-07-01 to 2024-09-300USD/shares92
2024-01-01 to 2024-09-30-0.01USD/shares274
2023-07-01 to 2023-09-300USD/shares92
2023-01-01 to 2023-09-30-0.01USD/shares273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-09-30213,116USD
At 2023-12-3113,723USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-09-301,491,833USD274
2023-01-01 to 2023-09-300USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-327,307USD92
2024-01-01 to 2024-09-30-4,446,540USD274
2023-07-01 to 2023-09-30-2,468,553USD92
2023-01-01 to 2023-09-30-3,197,279USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-09-30371,039USD
At 2023-12-31652,664USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2024-01-01 to 2024-09-30383,906USD274
2023-01-01 to 2023-12-31292,190USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-09-303,518,334USD
At 2023-12-312,787,177USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-09-30492,713USD
At 2023-12-31241,695USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2024-09-307,105,522USD
At 2023-12-310USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2024-09-309,671,687USD
At 2023-12-3149,363USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2024-09-3019,442USD
At 2023-12-31104,581USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-07-01 to 2024-09-30808,955USD92
2024-01-01 to 2024-09-305,782,224USD274
2023-07-01 to 2023-09-303,039,754USD92
2023-01-01 to 2023-09-305,130,682USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2024-09-30158,726USD
At 2023-12-31217,529USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2024-07-01 to 2024-09-30481,648USD92
2024-01-01 to 2024-09-301,335,684USD274
2023-07-01 to 2023-09-30571,201USD92
2023-01-01 to 2023-09-301,933,403USD273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2024-07-01 to 2024-09-30114,389USD92
2024-01-01 to 2024-09-30543,933USD274
2023-07-01 to 2023-09-30223,343USD92
2023-01-01 to 2023-09-30800,004USD273

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2024-07-01 to 2024-09-30236,279USD92
2024-01-01 to 2024-09-303,982,443USD274
2023-07-01 to 2023-09-302,963,602USD92
2023-01-01 to 2023-09-304,734,930USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-07-01 to 2024-09-300USD92
2024-01-01 to 2024-09-3014,543USD274
2023-07-01 to 2023-09-3080,781USD92
2023-01-01 to 2023-09-30175,072USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-09-30956,530,100shares
At 2023-12-31770,833,296shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-09-3070,081USD
At 2023-12-31125,402USD
At 2023-09-3057,963USD
At 2022-12-31616,696USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-09-3029,777,603USD
At 2023-12-319,676,656USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2024-09-30-1,943USD
At 2023-12-31-942USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-09-300USD
At 2023-12-31150,000USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-09-30426,725USD
At 2023-12-31346,677USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-09-30122,790USD
At 2023-12-31205,152USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-397,421USD92
2024-01-01 to 2024-09-30-4,654,447USD274
2023-07-01 to 2023-09-30-2,519,035USD92
2023-01-01 to 2023-09-30-3,323,602USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2024-07-01 to 2024-09-3012,377USD92
2024-01-01 to 2024-09-3022,778USD274
2023-07-01 to 2023-09-301,193USD92
2023-01-01 to 2023-09-303,580USD273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2024-07-01 to 2024-09-30562,089USD92
2024-01-01 to 2024-09-301,621,949USD274
2023-07-01 to 2023-09-300USD92
2023-01-01 to 2023-09-300USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-67,553USD92
2024-01-01 to 2024-09-30-206,906USD274
2023-07-01 to 2023-09-30-50,482USD92
2023-01-01 to 2023-09-30-146,055USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-01-01 to 2024-09-3070,430USD274
2023-01-01 to 2023-09-3067,397USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2024-01-01 to 2024-09-300USD274
2023-01-01 to 2023-09-30815,053USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-85,139USD274
2023-01-01 to 2023-09-30-1,442USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-58,803USD274
2023-01-01 to 2023-09-30-2,412USD273

Inspect the source

Entity
BIOREGENX, INC. / CIK 0001593184
Captured
2026-09-20T09:24:22.062Z
SEC response SHA-256
dcc795fc627ecba421235f598ce57edda4a944d38cb0c37c9ed973fb2243d52d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001593184.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))